Blink, and you may have missed it: over half of Denmark’s 5.8 million inhabitants have had at least one jab.
In fact, as we enter today, the total number is only 226 shy of the 3 million mark, and remember: at present, there are no plans to vaccinate the age group 0-12.
Johnson & Johnson: close to 1 percent of the population
In addition, over 28 percent are now fully vaccinated, and it seems that this number has had some help from our friends at Practio.
Yesterday, the private vaccinator confirmed that 45,653 people in Denmark have received one of the discarded vaccines, most of whom chose Johnson & Johnson single-jab solution instead of AstraZeneca – so close to 1 percent of the total population.
Doctors who reject a quarter of the female applicants
The majority who receive the vaccination are men, as only 16 percent of male applicants are rejected during the consultation process compared to 28 percent of women.
Hearsay and photographic evidence from centers such as the one at DGI-Byen near Copenhagen Central Station also suggest that the majority of the people who receive the vaccine are men.
Practio confirms gender difference due to side effect risk
“There is a significant difference,” Jonas Nilsen, co-founder of Practio, confirmed to DR.
“The rare risk of side effects is somewhat less for men than women, and it therefore takes more for a doctor to prescribe a vaccine for a woman.”
The National Board of Health: But men also face a risk!
It has long been documented that women who have received hormone therapy, such as birth control pills or a menopausal treatment, have a significantly higher risk of developing the rare side effect VITT, which causes the development of blood clots.
But men can also develop VITT syndrome, according to a Department of Health health note issued on May 3, though Practio insists more data has become available since then, further supporting that women are more vulnerable.
Still no conclusions from the drug agency
The Danish Medicines Agency has not yet concluded whether the risk is greater for women, even though they have suffered a greater number of side effects.
“With the knowledge we have today, there is no reason to assess men and women differently in the optional scheme,” said Anne-Mette Hvas, a blood clot expert at Aarhus University Hospital, to DR.
Source: The Nordic Page